Pharmesis International Ltd. (SGX: BFK)

Market Cap	18.07M
Revenue (ttm)	7.80M
Net Income (ttm)	-1.38M
Shares Out	31.70M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.600
Previous Close	0.600
Day's Range	0.600 - 0.600
52-Week Range	0.065 - 0.700
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About Pharmesis International

Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People’s Republic of China. The company provides prescribed products and over-the-counter drugs. It offers western medicine products under the Kinna brand, including Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Compound Procaine hydrochloride to treat arterioscler...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 1,096
• Stock Exchange: Singapore Exchange
• Ticker Symbol: BFK

Financial Performance

In 2023, Pharmesis International's revenue was 45.64 million, a decrease of -9.40% compared to the previous year's 50.37 million. Losses were -4.96 million, 39.3% more than in 2022.

Financial numbers in CNY